Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program?

被引：43
作者：
Mangen, Marie-Josee J. [1 ,2 ]
van Duynhoven, Yvonne T. H. P. [2 ]
Vennema, Harry [2 ]
van Pelt, Wilfrid [2 ]
Havelaar, Arie H. [2 ,3 ]
de Melker, Hester E. [2 ]
机构：
[1] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 GA Utrecht, Netherlands
[2] Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands
[3] Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands
来源：
VACCINE | 2010年 / 28卷 / 14期
关键词：
Rotavirus vaccination; National immunization program; Cost-effectiveness; RISK-FACTORS; DISEASE BURDEN; GASTROENTERITIS; ENGLAND; HOSPITALIZATIONS; NETHERLANDS; INFECTIONS; EFFICACY; INFANTS; CAMPYLOBACTER;
D O I：
10.1016/j.vaccine.2010.01.014
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
This study assessed whether the inclusion of two rotavirus (RV) vaccines in the Dutch national immunization programme is cost-effective. Costs and outcomes in unvaccinated and vaccinated populations are compared for a time period of 20 years. In the baseline, assuming competitive market forces in relation to vaccine costs, Rotarix (R) is more cost-effective than RotaTeq (R), resulting in a cost-utility ratio (CUR) of (sic) 53,000 per DALY (third payer perspective) and (sic) 49,000 per DALY (societal perspective), but both considered as being not cost-effective. Vaccine-related costs, annual epidemic-size, and indirect protection are the major factors that determine cost-effectiveness of RV vaccination. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码：2624 / 2635
页数：12
相关论文
共 64 条
[61]  
WELTE R, 2001, 39 ANN M INF DIS SOC
[62]   Assessing the introduction of universal rotavirus vaccination in the Netherlands [J].
Zomer, T. P. ;
van Duynhoven, Y. T. H. P. ;
Mangen, M. J. J. ;
van der Maas, N. A. T. ;
Vennema, H. ;
Boot, H. ;
de Melker, H. E. .
VACCINE, 2008, 26 (29-30) :3757-3764
[63]  
2000, FOOD STANDARDS A REP
[64]  
2006, INFECT B, V17, P235
1234567